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ABSTRACT 
PARAOXONASE 2 IS CRITICAL FOR NON-SMALL CELL LUNG CARCINOMA 
PROLIFERATION 
Aaron Whitt 
December 13, 2018 
Non-small cell lung carcinoma (NSCLC) comprises 85% of lung cancer 
diagnoses and is plagued by drug resistance. Thus, elucidating the underlying 
mechanisms of NSCLC is paramount to expand future treatment options. 
Paraoxonase 2 (PON2), an intracellular enzyme with arylesterase and lactonase 
functions, has well-established anti-atherosclerotic activity. Recent studies show 
PON2 is overexpressed in a variety of tumors and confers drug resistance, 
although these interactions have not been thoroughly examined in NSCLC. Thus, 
we sought to investigate the role of PON2 in cellular proliferation using PON2-
knockout mice, primary mouse cells, and NSCLC cell lines. Using these 
approaches, we demonstrate that PON2 is required for NSCLC proliferation, but 
dispensable for normal mouse development and non-transformed cell proliferation. 
These observations highlight PON2 as a potential therapeutic target against 
NSCLC. 
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CHAPTER 1: INTRODUCTION 
1. Paraoxonases
The paraoxonases (PONs) comprise 3 members (PON1, PON2, and 
PON3)  of an antioxidant enzyme family encoded in a gene cluster on the long arm 
of chromosome 7 (7q21.3-22.1) [1]. These enzymes are evolutionarily ancient, first 
appearing in invertebrates, and are highly conserved in mammals, displaying 80-
95% sequence identity at both the amino acid and nucleotide level [2]. PON2 is 
presumed to be the oldest, eventually giving rise to PON1 and PON3 through gene 
duplication events [3]. All PONs exhibit lactonase and arylesterase activity, but are 
otherwise functionally diverse [4]. For instance, PON1 was first discovered and 
named for its ability to hydrolyze paraoxon, the toxic metabolite of the 
organophosphate insecticide, parathion [5]. Although their name would suggest 
the contrary, PON2 and PON3 lack this paraoxon-detoxifying activity but retain the 
designation based on genetic homology. Intriguingly, no endogenous substrates 
have been identified for this class of enzymes. 
1.1 PON1 
PON1 is the most characterized of the PONs. Early work on PON1 focused 
on its xenobiotic metabolizing capability, specifically in the context of 
organophosphate detoxification, [6], [7].  Recent and emerging PON1 research,
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however, has shifted to exploring its role in atherosclerosis, immunity, and cancer 
[8]. The PON1 gene encodes a 43 kDa protein consisting of 354 amino acids [9] 
which is produced by the liver and released into circulation where it associates with 
high-density lipoprotein (HDL) particles and is distributed throughout the body [10]. 
Once in the serum, PON1 inhibits and reverses the oxidization of low-density 
lipoproteins (LDL), an initiating step in the development of atherosclerosis [11]. 
This effect has been extensively demonstrated in cell-based systems and in 
PON1-knockout mice[11]–[14]. Additionally, a number of human studies have 
suggested a relationship between polymorphisms in the coding and promoter 
regions of the human PON1 gene and susceptibility to cardiovascular disease [15]. 
The sheer abundance of research linking PON1 status to atherogenesis has 
sparked much interest in PON1 as a biomarker and/or therapeutic target against 
oxidative vascular damage [16]. 
PON1 has also been shown to mediate bacterial infection. Through its 
lactonase activity, PON1 can cleave a class of bacterial quorum-sensing 
compounds, the acyl-homoserine lactones [17]. The hydrolysis of the lactone ring 
effectively inactivates acyl-homoserine lactones and disrupts bacterial intercellular 
communication and colonization of host tissues. 
The antioxidant and anti-inflammatory properties of PON1 have prompted 
researchers to investigate its role in cancer. Indeed, several published reports 
confirm a link between PON1 and cancer. An investigation conducted by 
Marchesani et al. monitored prostate cancer development in a population of 
Finnish men and found a specific PON1 single nucleotide polymorphism (SNP), 
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I102V, was associated with increased incidence [18]. Similarly, Stevens et al. 
discovered the L55M SNP correlated to an increased risk of breast cancer in a 
cohort of post-menopausal women [19]. More recently, Aldonza et al. used data 
from the cancer genome atlas (TCGA), lung cancer patient samples, and lung 
cancer cell lines to show that PON1 provides an anti-apoptotic function to stimulate 
tumor growth and progression [20]. While these observations are promising, the 
underlying mechanisms remain undetermined. 
1.2 PON3 
In contrast to PON1, PON3 is the most recently-identified and least-studied 
member of this family. PON3 is a 40 kDa protein synthesized mainly by the liver 
and, to a lesser extent, the kidney which associates with circulating plasma HDLs 
[21]. In circulation, PON3 is capable of detoxifying oxidized LDLs (oxLDLs) at a 
higher capacity than PON1, although circulating levels of PON3 are much lower 
than PON1 [21]. PON3 has also been detected intracellularly, localized to 
endoplasmic reticulum (ER) and mitochondria [22], [23]. Similar to its other family 
members, PON3 elicits anti-inflammatory, anti-oxidant responses in vitro and in 
vivo which have been connected to atherosclerosis, diabetes, neurodegenerative 
disorders, and cancer [2], [5], [24]. 
1.3 PON2 
PON2, unlike the other PONs, is expressed intracellularly in nearly every 
tissue surveyed [25], where it localizes to mitochondria, ER, and nuclear lamina 
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[26] as a transmembrane protein with a molecular mass of 43 kDa [27]. PON2 
shares anti-oxidant and anti-inflammatory characteristics with other PONs, such 
as preventing and reversing oxidative damage to LDL [25]. In addition, PON2 also 
exerts intracellular influence, generally by mitigating oxidative stress in 
mitochondria and ER. Its widespread tissue distribution and subcellular 
localization implicate PON2 in a variety of physiological processes 
1.3.1 PON2 and Atherosclerosis 
PON2 is perhaps most thoroughly characterized as a mitigating factor in the 
development of atheromatous plaques. Although it is not known to bind to HDL 
particles directly, PON2 exerts a protective effect against vascular damage. 
Indeed, this was expertly demonstrated in separate studies using PON2-deficient 
mice challenged with a high-fat diet [28]–[30]. The first of these studies, carried out 
by Ng et al., reported that mice deficient in PON2 fed on a high-fat diet developed 
larger atherosclerotic lesions than their wild type counterparts [30]. Paradoxically, 
PON2-deficient mice had lower serum levels of very low-density lipoprotein (VLDL) 
and LDL, which are known to contribute to atherogenesis. However, VLDL/LDL 
isolated from PON2-deficient mice were significantly more inflammatory to 
monocytes in vitro than the same lipoproteins isolated from wild type mice [30]. 
Later studies conducted by Devarajan et al. expanded these findings using PON2-
deficient mice crossed to hyperlipidemic ApoE-/- mice to demonstrate that PON2 
protected against atherosclerotic plaque formation by reducing the mitochondrial 
formation of reactive oxygen species (ROS) at complex III of the electron transport 
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chain (ETC) [29]. A further study by the same group showed that PON2 modulates 
ER stress by stabilizing calcium homeostasis in macrophages, ultimately 
promoting cellular survival [28]. These animal studies, taken in conjunction with 
abundant in vitro evidence, demonstrate that PON2 is major component of 
atherosclerosis pathophysiology. 
1.3.2 PON2 and Type II Diabetes Mellitus 
The link between PON2 and type II diabetes mellitus (T2DM) is largely 
speculative and is grounded in PON1’s influence on T2DM and the larger 
contribution of systemic inflammation and oxidative stress on T2DM development 
and severity. Despite numerous reports of an association between the A148G 
PON2 variant and T2DM, a recently published meta-analysis failed to reach the 
same conclusion [31]. However, a study conducted on an Iranian population of 
healthy and diabetic patients reported a positive correlation with another PON2 
variant, S311C [32]. Based on the lack of consensus in this regard, more research 
into PON2’s impact on T2DM is required. 
1.3.3 PON2 and Cancer 
Research efforts in the last decade have broadened their focus to include 
PON2’s role in cancer. During this period, a clearer picture of how PON2 activity 
influences neoplastic tissue has begun to develop. Generally, PON2 has been 
shown to contribute to apoptotic escape and chemotherapeutic resistance through 
its ability to scavenge ROS in mitochondria and mitigate ER stress [8], [24], [33].  
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However, these effects have only been observed in a limited variety of cancers. 
Further work is required to understand the full pro-tumorigenic mechanisms of 
PON2. Nonetheless, work up to this point has provided a substantial springboard 
for future studies. 
The first recorded implication of PON2 in the context of cancer was 
conducted by Frank et al. who investigated gene expression patterns in patients 
with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia 
(CML) that failed to respond to the kinase inhibitor imatinib [34]. At the time, 
acquired resistance to imatinib was well-documented, so this group sought to 
uncover genes that mediate primary resistance. Leukocyte RNA was isolated from 
Ph+ patients with CML that were classified as either responders or non-responders, 
converted to cDNA, and analyzed using microarray hybridization technology. In 
non-responders, genes involved in oxidative stress, apoptosis, and DNA repair 
were identified as being significantly up- or down-regulated [34]. Among proteins 
with the highest fold change was PON2. Overall, the researchers identified over 
100 genes that contributed to primary imatinib resistance in Ph+ patients with CML. 
To our knowledge, this is the first report drawing an association between PON2 
and cancer. 
Shortly thereafter, Altenhofer et al. hypothesized that superoxide (O2-) 
scavenging activity of PON2 at the mitochondrial inner membrane would promote 
tumor survival [35]. O2- dismutates (via superoxide dismutase, SOD; or 
spontaneously) to H2O2 which leads to the release of cytochrome c from 
mitochondria and ultimately activates the intrinsic apoptotic cascade, resulting in 
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cell death [36]. In the study, investigators sought to determine whether PON2’s 
anti-oxidant activity was reliant on its lactonase activity. Using a site-directed 
mutagenesis approach, the researchers showed that PON2 retains its anti-oxidant 
functions independent of its lactonase activity [35]. Although not directly a cancer-
related study, the authors were among the first to suggest a pro-tumorigenic role 
for PON2. 
Another early study implicating PON2 in human cancer was conducted by 
Kang et al. [37]. Investigators measured relapse-free survival (RFS) of patients 
with high-risk pediatric acute lymphoblastic leukemia (ALL) for a maximum of 6 
years. The stated goal of this investigation was to strengthen predictions in patient 
outcomes and improve the existing risk classification system for patients with 
pediatric ALL.  To this purpose, patients were separated into low- and high-RFS 
populations and DNA microarray data were integrated with cytometric measures 
to assemble a unique gene expression profile to predict RFS. Of the 38 genes 
most strongly correlated with RFS, PON2 expression was negatively correlated 
with RFS; i.e. patients with high PON2 expression relapsed earlier than patients 
with low PON2 expression [37]. Although indirectly, the results of this study further 
suggested that PON2 serves to promote carcinogenesis. 
In a paper published by Witte et al., a dual role for PON2 in tumor cell 
pathophysiology was established [38]. The same group of researchers had, a year 
earlier, proposed that PON2’s role in reducing oxidative stress may contribute to 
tumorigenesis [35]. This study focused on redox homeostasis and ER stress 
pathways in tumor cells, based on PON2’s subcellular localization with 
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mitochondria and the ER, and cell death/stress pathways mediated by these 
organelles. First, the investigators compared PON2 expression in tumor vs. normal 
tissues isolated from over 400 patients with cancer. Using this approach, they 
found high relative expression (>2 fold) of PON2 in tumors from uterus, liver, 
kidney, lymphoid tissues, or urinary bladder; and moderate relative expression 
(~1.5 fold) of PON2 in tumors from the thyroid gland, prostate, pancreas, and testis 
[38]. One possible limitation of this methodology is that samples were pooled—all 
tumor samples of a given subtype were combined, and all normal tissue samples, 
likewise—making pairwise comparisons impossible. Thus, relative PON2 
upregulation may have been missed due to inter-patient variability in baseline 
PON2 expression. Next, PON2 was either ectopically overexpressed or knocked 
down via RNA interference (RNAi) in a wide variety of healthy and malignant cell 
lines. The results of these experiments indicate that PON2 overexpression blunts 
the cytotoxic effects of chemotherapeutic agents, and that knockdown increases 
apoptotic sensitivity [38]. Finally, mechanistic insight was provided by a series of 
traditional biochemical experiments demonstrating that PON2 prevents the ER-
stress mediated induction of pro-apoptotic CHOP (CCAAT/-enhancer-binding 
protein homologous protein) and inhibits intrinsic apoptotic signaling [38]. These 
observations confirmed an earlier hypothesis and paved the way for future PON2 
studies in the context of cancer. 
PON2’s protective role in tumor cells was further demonstrated in the 
context of oral squamous cell carcinoma (OSCC). A report published in 2015 
describes the stabilizing effect of PON2 expression on radiation-induced apoptosis 
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in OSCC cells [39]. The study explored activation of the intrinsic apoptotic signaling 
cascade following irradiation in various OSCC cell lines and correlated these 
responses with PON2 expression. In agreeance with previous studies, the OSCC 
cells that overexpress PON2 exhibit lower induction of cell death than those with 
lower PON2 expression—an effect which was reversible by RNAi-mediated 
knockdown of PON2 [39]. A subsequent study reported the involvement of the 
Wnt/β-catenin pathway in regulating PON2 expression [40]. Researchers identified 
sites in the PON2 gene promoter that are bound by transcription factors involved 
in Wnt/β-catenin signaling using a computational approach, a liquid 
chromatography-mass spectrometry (LC-MS) based proteomics method, and a 
siRNA assay screen. Employing traditional biochemical approaches,  it was then 
demonstrated that PON2 is directly regulated by ligands of Wnt and its upstream 
transcription factors [40]. This regulatory network was not previously explored and 
has yet to be validated in another tumor type. Nonetheless, this work enhances 
our current mechanistic understanding of the apoptotic resistance afforded by 
PON2.  
 Recently, PON2 was identified in an integrative genomics study of 
pancreatic ductal adenocarcinoma (PDAC) by Nagarajan et al [41]. Once identified 
in silico and validated in an initial screen, PON2 was knocked down via shRNA-
mediated RNAi and subsequently diminished metastasis of PDAC cells in multiple 
in vivo models [41]. Further in silico analysis coupled with chromatin-
immunoprecipitation (ChIP) assays also revealed transcriptional repression of 
PON2 by p53, which was previously undocumented. Intriguingly, this study also 
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demonstrated that PON2 expression may modulate glucose uptake by stimulating 
GLUT1-mediated glucose transport. This work reveals a regulatory pathway by 
which PON2 promotes tumor survival and metastasis, although, further work is 
required to determine whether these interactions are present in other cancer types, 
or if the observations described in this report are specific to PDAC alone. 
Largely, this body of work provides a cohesive lens through which PON2’s 
tumor-promoting role may be viewed. Although the complete mechanisms and 
interactions have not been fully established, PON2 confers apoptotic resistance to 
tumor cells by abating ER stress and reducing ROS formation in mitochondria. 
This protection enables various tumor cells to overcome the cytotoxic effects of 
chemotherapeutics [34], [38] and irradiation [39], [40], and promotes metastasis 
[41]. Additionally, PON2 receives and exerts regulatory control through commonly-
dysregulated oncogenic networks, such as the Wnt/β-catenin pathway [40] and 
p53 [41]. In conjunction with large-scale studies that have demonstrated that PON2 
is upregulated in numerous and diverse tumor types [38], [42], these 
considerations necessitate further study of PON2’s oncogenic contribution in other 
neoplastic tissues and cells. 
2. Non-small cell lung carcinoma
Lung cancer claims more lives each year than any other cancer in the US 
and globally [43]. Non-small cell lung carcinoma (NSCLC) is the dominant subtype 
of lung cancer, comprising 85% of all diagnoses [44]. Under the umbrella of 
NSCLC are three distinct histological subtypes: Adenocarcinoma is the most 
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frequently indicated histology of NSCLC and accounts for 35-40% of lung cancer 
cases; Squamous cell carcinoma accounts for 25-30% of cases and is most 
common in smokers; The remaining NSCLC diagnoses are classified as Large cell 
carcinoma, which accounts for around 10% of all lung cancer diagnoses [45]. 
Although tumors of a given histological subtype share morphological 
characteristics, next generation sequencing technology has  revealed a high 
degree of heterogeneity, complicating therapeutic intervention [44]. Indeed, the 
intra- and inter-tumoral variability may contribute to the near-inevitability that 
patients with NSCLC will develop drug resistance during treatment [44]. With these 
considerations in mind, it is perhaps unsurprising that 5-year survival in patients 














While numerous studies have implicated PON2 overexpression in a variety 
of tumor types with respect to chemotherapeutic resistance, tumorigenesis, 
disease progression, and metastasis, PON2’s impact on NSCLC treatment is 
poorly understood. In the present study, we sought to explore the potential 
interplay between PON2 expression and NSCLC proliferation using knockout 
animals, human and mouse tissue samples, primary cells, NSCLC cell lines, and 
non-transformed human epithelial cells. These insights will broaden our 
understanding of NSCLC pathophysiology, which will enhance future treatment 
options and improve outcomes for patients with NSCLC. 
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CHAPTER 2: METHODS 
Reagents 
Dulbecco’s Modified Eagle’s Medium (DMEM), penicillin/streptomycin, 
trypsin, and L-glutamine were obtained from Mediatech (Manassas, VA); fetal 
bovine serum was purchased from Gemini (Broderick, CA); Bronchial Epithelial 
Cell Growth Medium (BEGM) and SingleQuots were purchased from Lonza 
(Walkersville, MD); and propidium iodide and β-Mercaptoethanol were purchased 
from Invitrogen (Carlsbad, CA). N-(3-oxododecanoyl)-homoserine lactone (C12), 
polybrene and puromycin were purchased from Sigma-Aldrich (St. Louis, MO). 
Antibodies (Abs) for western blot were anti-β-actin mAb (A5441; Millipore Sigma; 
Burlington, MA), anti-Human PON2 mAb (ab183710; Abcam; Cambridge, 
England), anti-Mouse PON2 pAb (ABIN1573944; antibodies-online.com; Atlanta, 
GA), peroxidase-conjugated goat anti-rabbit IgG (65-6120; Thermo Fisher; 
Waltham, MA) and peroxidase-conjugated goat anti-mouse IgG (65-6520; Thermo 
Fisher). 
Cell culture 
HEK-293T, A549, and NCI-H1299 cell lines were purchased from ATCC 
(Manassas, VA).  Human bronchia/tracheal epithelial (HBE) immortalized by 
telomerase and SV40 large T antigen were obtained from Professor Barrett Rollins 
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(Harvard Medical School).  HBE cells were cultured in BEGM supplemented with 
SingleQuots. All other cells were cultured in DMEM containing 10% FBS, 100 
units/mL penicillin, and 100 g/mL streptomycin. All cell lines were cultured in a 
5% CO2 humidified incubator at 37oC. The cells were passaged at 1:5–1:10 
dilutions and were continuously cultured no longer than 3 weeks. All stocks come 
from thawed vials that were frozen at passage two after receipt from ATCC and 
were authenticated by ATCC cell bank using the Short Tandem Repeat (STR) 
profiling. 
Plasmids 
Control double nickase plasmid (SC-437281) and PON2 CRISPR/Cas9 
plasmid (SC-403181-NIC) were purchase from Santa Cruz (Santa Cruz, CA). 
Control double nickase plasmid comprises a pair of plasmids, each with D10A 
mutant Cas9 nuclease and a non-targeting 20nt scramble gRNA. While one 
plasmid in the pair contains a puromycin-resistance gene, the other plasmid in the 
pair contains a GFP marker to visually confirm transfection. PON2 CRISPR/Cas9 
knockout plasmid comprises 2 pooled plasmids, each encoding the Cas9 
nuclease, a PON2-specific 20nt gRNA, and a selection marker. One Plasmid 
contains a puromycin-resistance gene and the other plasmid has a GFP marker. 
gRNA sequences direct the Cas9 protein to induce a site-specific double strand 
break (DSB) in exon 3 of PON2 genomic DNA. Control shRNA plasmid-A 
(SC108060) and PON2-shRNA plasmids (SC62838) were purchased from Santa 
Cruz. Control shRNA plasmid-A encodes a non-specific scramble shRNA; PON2-
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shRNA plasmid comprises 3 lentiviral vector plasmids with 19-25nt shRNAs 
targeted to PON2. Each shRNA plasmid contains a gene for puromycin resistance 
as a selection marker. Lentiviral helper plasmids pMDLg/pRRE (12251), 
pRSV.Rev (12253) and pMD2.G (12259) were purchased from Addgene 
(Watertown, MA). The identities of each plasmid were verified by sequencing. 
 
Generation of cells with reduced PON2 expression by shRNA 
HEK-293T cells (1.5*106) were plated in 6-cm tissue culture plates and 
cultured for 24 hours. To produce lentivirus, HEK293T cells were transfected with 
control shRNA plasmid-A (SC108060) or PON2-shRNA plasmids (SC62838) 
along with the lentiviral helper plasmids pMDLg/pRRE, pRSV.Rev and pMD2.G 
using Lipofectamine2000® transfection reagent (Thermo Fisher) as a lipid 
transport milieu. Tissue culture medium containing lentiviral particles was collected 
48- and 72-hours following transfection and was filtered through a sterile syringe 
filter with 0.4 M polyethersulfone membrane (VWR; Radnor, CA). Twenty-four 
hours prior to lentiviral infection, A549, HEK-293T and HBE cells (0.2*10^6) were 
seeded in 6-well tissue culture plates. To infect cells, the culture medium of plated 
cells were replaced with the medium containing lentiviral particles supplemented 
with 10 g/mL polybrene. The infection was repeated 24 hours later. Twenty-four 
hours after two rounds of infection, puromycin (5 g/mL) was added to the medium 
to kill uninfected cells. PON2 expression in the bulk population of infected cells 
was examined by western blot analysis. Bulk populations of infected cells were 
cultured in the medium supplemented with 1 g/mL puromycin. 
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Generation of cells deficient in PON2 expression by CRISPR/Cas9 
NCI-H1299 cells (2*106) were plated in 10-cm tissue culture plates and 
cultured for 24 hours. Control double nickase plasmid (SC-437281) and PON2 
CRISPR/Cas9 plasmid (SC-403181-NIC) were transfected into NCI-H1299 cells 
using Lipofectamine2000® transfection reagent (Thermo Fisher) following 
manufacturer’s protocol. Twenty-four hours after transfection, puromycin (5 g/mL) 
was added to the cell to eliminate untransfected cells. NCI-H1299 cells were grown 
in culture medium supplemented with 5 g/mL puromycin for 20 days until stably 
transfected cells grew up. Single clones of stably transfected cells were 
established by seeding single GFP-expressing cells into one well of 96-well tissue 
culture plates using fluorescence-activated cell sorting (FACS; MoFlo, Beckman 
Coulter, Brea, CA). Once GFP-positive cell clones grew up in the medium 
containing 5 g/mL puromycin, PON2 expression in cloned cell lines were 
examined by western blot analysis. To ensure stable plasmid expression, cells 
were grown in culture medium supplemented with 1 g/mL puromycin. 
Western Blot analysis 
Tissue lysates were prepared using human lung tumor samples from 
patients with NSCLC and organ tissue derived from wild type or PON2-knockout 
mice as follows: Frozen tissue samples were resuspended in tissue protein 
extraction reagent (Thermo Fisher) supplemented with protease inhibitors 
(cOmplete; Roche; Indianapolis, IN) and phosphatase inhibitors (PhosSTOP; 
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Roche). Following homogenization and centrifugation, protein concentration was 
determined by bicinchoninic acid (BCA assay) (Thermo Fisher). Whole cell 
extracts of cultured mammalian cells were acquired using RIPA buffer (Thermo 
Fisher) supplemented with protease inhibitors (cOmplete; Roche). For human 
tissue, 30 g of total protein was electrophoresed; for mouse organ tissue, 10 g 
of total protein was used; for cultured cells, 30 g of total protein was analyzed. All 
of the samples were electrophoresed in 4–12% Bis/Tris gels (Bio-Rad; Hercules, 
CA). Separated proteins were transferred to a polyvinylidene difluoride (PVDF) 
membrane (Millipore) and incubated with respective primary or secondary 
antibodies diluted with 10% (w/v) nonfat dry milk (Bio-Rad) in blotting buffer (1X 
phosphate-buffered saline [PBS] with 0.2% Tween-20). The enhanced 
chemiluminescence detection system (Thermo Fisher) was used to detect proteins 
as previously described [47]. ImageJ software (NIH, Bethesda, MA) was used to 
quantify the Optical density (OD) values of western blot signals. 
 
Cell death assays 
The indicated MEF cells were plated in a 48‐well tissue culture plate with 
10,000 cells in each well and cultured for 24 hours. Unless otherwise stated, 
medium containing 0.2% DMSO with or without C12 was incubated with the cells. 
Following treatment with DMSO or C12, cells were harvested in the presence of 1 
μg/ml propidium iodide (PI). Cell viability was measured by PI exclusion using flow 
cytometry (FACScalibur, Beckon Dickinson, San Jose, CA). The percentage of cell 
death was determined as100 minus the value of cell viability measurement. 
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Cellular proliferation experiments 
Proliferation was assessed by a cell counting method using a 
hemocytometer. Equal numbers of cells were plated and cultured in 12-well plates 
with 3 replicates for 4 time points: 24, 48, 72, and 96 hours. Initial cell number was 
selected based on cell size and proliferation rate as follows: 1.5*104 HBE cells 
(control- and PON2-shRNA); 1.5*104 HEK-293T cells (control- and PON2-shRNA); 
1.5*104 A549 cells (control- and PON2-shRNA); 1.5*104 NCI-H1299 cells (vector 
clones 2 and 3; CRISPR-PON2 clones 4 and 14). 
Cell cycle analysis 
A549 cells (5*105) were centrifuged at 300 x g for 5 minutes and washed 
twice with 500 µl 1X PBS. Cells were then fixed with 1 ml 70% ethanol in 1X PBS 
at 4oC overnight.  After centrifugation (300 x g for 5 minutes), cells were washed 
twice with 1X PBS and resuspended in 500 µl 1X PBS. 50 U RNase A (Qiagen; 
Valencia, CA) were added to samples followed by incubation at 37oC for 1 hour. 
Then propidium iodide (5 µg) was added to samples which were incubated for 30 
minutes at 37oC before flow cytometric analysis (FACScalibur). 
Liquid Chromatography-Mass Spectrometry 
Lysates from mouse organ tissues and primary MEF cells were prepared 
according to a published method [48], with minor modifications. Mouse organs 
were harvested and thoroughly rinsed with 1X PBS, flash-frozen in liquid N2, and 
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stored at -80oC. When needed, organ tissue was thawed on ice, to which 1 volume 
of lysis buffer (25 mM Tris/HCl containing 1 mM CaCl2 and supplemented with 
protease inhibitors [cOmplete; Roche] and phosphatase inhibitors [PhosSTOP; 
Roche]) was added. Tissue was sonicated on ice for 1 min. Lysates were 
centrifuged at 14,000 x g and 4oC for 10 min. Supernatant protein concentration 
was determined using the BCA assay (Thermo Fisher). Final protein concentration 
was adjusted to 2 µg/µL in lysis buffer. 
Primary MEF cells were seeded into 10 cm tissue culture plates at a 
concentration of 106 cells per plate and cultured overnight. Cells were collected by 
trypsinization and cell number was determined using a hemocytometer. 106 cells 
were centrifuged at 300 x g, supernatant was aspirated, and cells were 
resuspended in 1 mL ice-cold 1X PBS. Wash step was repeated once more, then 
cells were centrifuged at 5000 x g and 4oC for 5 min and supernatant was removed 
by aspiration. Cell pellets were stored at -80oC. When needed, cells were thawed 
on ice, to which 100 µL lysis buffer was added to resuspend cells. Cells were 
sonicated on ice for 10 sec. Lysates were centrifuged at 14,000 x g and 4oC for 10 
min. Supernatant protein concentration was determined using the BCA assay 
(Thermo Fisher). Final protein concentration was adjusted to 2 µg/µL in lysis buffer. 
10 µg of total protein from mouse organ tissue lysate or primary MEF cell 
lysate was diluted to a final volume of 100 µL in 5 mM Tris/HCl (ph 7.4) containing 
1 mM CaCl2. Reactions were initiated with either 1% MeOH or 1% 5 mM C12 (in 
Methanol; final concentration 50 µM C12) and incubated at 37oC for 30 min. The 
reaction was stopped with 70 L of ice-cold acetonitrile and immediately analyzed 
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by liquid chromatography–mass spectrometry (LC-MS) without further 
manipulation. LC-MS experiments were carried out at the University of Louisville 
medicinal chemistry core facility. A sample volume of 15 µL was injected into an 
Agilent 1260 HPLC system (Agilent; Santa Clara, CA) equipped with an Agilent 
6224 Accurate-Mass Time-of-Flight MS utilizing electrospray ionization. The HPLC 
system was equipped with an Zorbax Extend-C18 column (1.8 μm, 2.1 × 50 mm; 
Agilent) with a mobile phase consisting of mass spectrophotometry grade water 
(with 0.1% formic acid and 0.1% methanol) and acetonitrile (with 0.1% formic acid) 
and operated in positive ion mode (3500 V V-Cap, 750 V OctRF Vpp, 65 V 
skimmer, 135 V fragmentor, 40 psi Nebulizer gas, 12 L/min drying gas, and 325oC 
gas temperature). Samples were eluted with a linear gradient of 5 to 100% 
acetonitrile at 0.3 mL/min over 10 min. Agilent software analysis suite was used to 
determine respective measured masses of spectrometry signals. 
In vivo animal studies 
Animals were housed in an AALAC- (Association for Assessment and 
Accreditation of Laboratory Animal Care) accredited pathogen-free barrier facility. 
All procedures were in accordance with the University of Louisville Institute for 
Animal Care and Use Committee (IACUC). Fertilized C57BL/6J-Tyrc-2J (i.e. B6 
Albino; Jackson Laboratory; Bar Harbor, ME) embryos were co-injected with Cas9 
mRNA and a sgRNA targeted to the mouse PON2 gene at exons 3. Treated mouse 
embryos were implanted into a pseudopregnant female mouse to resume 
gestation. Viable F0 pups were weaned, and genotypes were determined by 
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sequencing at the PON2 locus. An F0 pup was identified to be heterozygous for a 
single base-pair insertion in exon 3 that resulted in an early termination codon. 
Heterozygous mice were backcrossed to wild type C57BL/6J mice (Jackson) for 5 
generations to minimize genetic heterogeneity and simultaneously retain the 
mutant PON2 allele. Backcrossed offspring were selectively bred to achieve 
desired genotypes to be used in body weight and organ weight experiments. 
Genotyping of mice was carried out at the University of Louisville genomics core 
facility by sequencing mouse tail DNA. Body weight of C57BL/6J wild type and 
homozygous PON2-knockout mice was recorded biweekly from 1 month of age 
until 3 months, at which time heart, lungs, liver, kidneys, and spleen were dissected 
and weighed. 
 
Isolation of primary mouse embryonic fibroblast (MEF) cells 
Primary MEF cells were harvested and cultured according to a published 
protocol [49]. Briefly, embryos were aseptically dissected from female C57BL/6J 
mice at 13 days after a copulation plug was observed. Following removal of 
embryonic brain, heart, and liver, remaining tissue was finely minced using sterile 
scissors and incubated in 0.25% trypsin-EDTA for 10 min at 37oC. Solution was 
thoroughly agitated with a pipette and incubated for an additional 10 min at 37oC. 
Primary MEF medium (DMEM containing 10% FBS, 100 units/mL penicillin, 100 
μg/mL streptomycin, and 0.1 mM β-Mercaptoethanol) was added to deactivate 
trypsin and mixed using a pipette. Larger fragments were allowed to sink to tube 
bottom for 10 min, then cell suspension was plated in 15 cm tissue culture plates, 
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incubated at 37oC overnight, and refreshed with warm medium the following day. 
After 2 days, primary MEF cells were collected by trypsinization and resuspended 
in cryopreservation medium (10% DMSO in FBS), whereupon cells were aliquoted 
and stored in 2 mL cryovial tubes at -140oC for long-term storage. 
Lung tissues from patients with non-small cell lung carcinoma 
Tumor tissues along with corresponding adjacent normal tissues from 
patients with non-small cell lung carcinoma (NSCLC) were acquired from the 
James Graham Brown Cancer Center Bio-Repository at University of Louisville in 
accordance with an approved institutional review board (IRB) protocol. Tissue 
samples were stored at 37oC before experiments. 
Statistical analysis 
Data are presented as mean ± standard deviation. Proliferation studies 
were performed independently in triplicate. Animal weight studies were carried out 
with 10 animals per sex per group. Organ weight results are 5 per sex per group. 
A Student’s two-tailed unpaired t-test with p-value of < 0.05 was used to determine 
statistical significance. 
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CHAPTER 3: RESULTS 
PON2 is overexpressed in lung tumor samples from patients with NSCLC 
As discussed in the introduction, a number of studies have correlated PON2 
overexpression in a wide variety of solid tumors and blood cancers with 
tumorigenesis, disease progression, and chemotherapeutic sensitivity [34], [37], 
[38], [41], [42]. Of these studies, a limited number have focused on lung cancer in 
general [24], [42], but have failed to interrogate PON2 expression in NSCLC 
specifically.  To determine the relative expression level of PON2 in NSCLC, we 
acquired lung tumor samples from 11 patients with NSCLC and compared PON2 
protein levels with corresponding adjacent normal lung tissue using western blot 
analysis (Figure 1A). Optical density (OD) values for PON2 and actin were 
quantified using ImageJ software (NIH). Next, the OD values of PON2 were 
normalized to corresponding actin OD values for both normal and lung tumor 
samples, then the ratio of relative PON2 expression of lung tumor tissue vs. normal 
tissue was calculated (Figure 1B). Using this analytical approach, we found that 8 
of the 11 patients with NSCLC examined exhibited PON2 overexpression in lung 
tumor tissue, whereas PON2 expression was slightly decreased in the remaining 
3 patients. While PON2 expression levels among different NSCLC tumor tissue 
samples were consistently high, PON2 expression in normal tissue samples varied 
markedly. This might be attributed to different precancerous stages bearing
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 various premalignant lesions in adjacent normal tissues [50].  These data highlight 
a correlation between PON2 expression and malignant transformation in human 
patients with NSCLC, consistent with a recent study revealing a negative 
correlation between PON2 expression and patient prognosis of many cancer types 
[42]. 
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Figure 1. PON2 is upregulated in NSCLC tumor samples. (A) PON2 expression 
was evaluated in tumor (T) and adjacent normal lung (N) tissue samples derived 
from 11 patients with NSCLC.  (B) Optical density values in (A) were determined 
using ImageJ software (NIH) and used to calculate the ratio of PON2 expression 
(normalized to actin) in tumor tissue compared with corresponding adjacent normal 
lung tissue. Values greater than 1 indicate PON2 overexpression in tumor vs. 
normal tissue; 8 of 11 patient samples exhibited increased PON2 expression in 
NSCLC tissue.  
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Generation of PON2-knockout mice using CRISPR/Cas9 
 Ng and colleagues first generated PON2-deficient mice using a gene-
trapping method to investigate the impact of PON2 on atherogenesis [30]. While 
additional studies employing this mouse strain have further elucidated PON2’s 
effect on atherosclerosis, no studies have used PON2-deficient mice in the context 
of cellular proliferation and tumorigenesis. Since the PON2-deficient mice are not 
available to us and gene-trapping has a potential pitfall of allowing leaky 
expression of the trapped gene [51]–[53], we collaborated with the University of 
Louisville’s genomics core facility to employ a CRISPR/Cas9 approach to generate 
mice with systemic PON2 deletion. A single guide RNA (sgRNA) designed to target 
exon 3 of the PON2 gene was co-injected with Cas9 mRNA into fertilized 
C57BL/6/TyrC2J mouse embryos, then implanted into pseudopregnant female 
mice. Genotyping was performed by PCR and Sanger sequencing, which revealed 
an individual with a single nucleotide insertion in exon 3 that resulted in an early 
termination codon (Figure 2). This individual mouse was then outcrossed with wild 
type C57BL/6J mice whose progeny were further selectively outcrossed to retain 
the mutant PON2 allele. Following 5 generations of outcrossing, mice were bred 
to generate wild type (PON2+/+; WT), heterozygous (PON2+/-), and homozygous 





Figure 2. Generation of PON2-knockout mice using a CRISPR/Cas9 
approach. Fertilized C57BL/6J/TyrC2J embryos were co-injected with sgRNAs 
targeted to exon 3 the PON2 gene and Cas9 mRNA, then implanted in 
pseudopregnant female C57BL/6 mice. The PON2 locus was sequenced in each 
pup, revealing an individual with a single nucleotide insertion at exon 3 that 
resulted in an early termination codon.  Mice were selectively bred to expand the 
population carrying the mutant PON2 allele.  
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Tissues of PON2-knockout mice are deficient in PON2 protein expression 
To confirm that disrupting the genomic sequence of PON2 in mice leads to 
systemic deficiency in PON2 expression, we assessed PON2 expression in 
various organs. Although PON2 is a ubiquitously expressed protein, several major 
organs are known to produce relatively high levels of PON2 [25]. To this purpose, 
mouse tissues, including lung, stomach, small intestine and large intestine, were 
acquired from wild type (PON2+/+), heterozygous knockout (PON2+/-), and 
homozygous knockout (PON2-/-) mice. The protein levels of PON2 in the collected 
tissues were evaluated by western blot analysis. As shown in Figure 3, PON2 
protein was detected in all tissues isolated from wild type mice. Moreover, PON2 
protein levels in the tissues of heterozygous knockout mice were lower than their 
counterparts from wild type mice, which is in agreement with the number of intact 
PON2 allele in the tissues. Importantly, no PON2 protein was detected in any of 
the tissues from the mice with PON2 homozygous knockout, indicating that there 
is a systemic deficiency in PON2 protein expression in PON2 homozygous 
knockout mice. 
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Figure 3. Tissues from PON2-knockout mice lack PON2 expression. Tissues 
known to express PON2 at high levels (lungs, stomach, large intestine, and small 
intestine) were collected from wild type (+/+), heterozygous (+/-), and homozygous 
knockout (-/-) C57BL/6J mice and used to prepare tissue lysates. Western blot 
analysis was performed to determine mouse PON2 (mPON2; upper band) 
expression. Actin was detected as a loading control. The molecular weight markers 
are labelled on the left.  
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C12-induced cell death in primary MEFs depends on PON2 
PON2 is known to mediate mammalian cell death signaling triggered by 
various apoptotic stimuli, including N-(3-oxododecanoyl)-L-homoserine lactone (so 
called C12), a bacterial quorum-sensing molecule produced by Pseudomonas 
aeruginosa [1], [11]. Our previous studies indicate that PON2 is essential for 
apoptosis induced by C12 in a number of mammalian cell types, which is attributed 
to its lactonase activity [47], [54]. To further explore the biological consequences 
of PON2 expression deficiency in mice, we investigated how primary cells isolated 
from wild type or PON2-knockout mice respond to C12 exposure. To this purpose, 
we first isolated primary MEFs from 13 day-old embryos and examined PON2 
expression by western blot analysis. As shown in Figure 4A, PON2 protein 
expression in MEFs generated from PON2-knockout mice was not detected, which 
is in agreement with the data acquired from tissue samples (Figure 3). Upon 
treatment with different doses of C12, wild type MEFs underwent cell death in a 
dose-dependent fashion (Figure 4B). In contrast, cytotoxicity of C12 was 
completely abrogated in MEFs lacking PON2 expression, consistent with our 
earlier findings about the vital role of PON2 in C12-induced cell death [47], [54]. 
Overall, these data provide more evidence that deleting PON2 gene expression in 
mice affects how cells respond to apoptotic stimuli. 
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Figure 4. Primary MEFs are sensitive to C12-mediated cell death in a PON2-
dependent manner. (A) Primary MEF cells were isolated from either wild type or 
PON2-knockout mice, and PON2 expression was assessed via western blot 
analysis. Actin was detected as a loading control. The molecular weight markers 
are labelled on the left. (B) PON2 is required for the cytotoxic effects of C12. To 
assess PON2 function in primary MEF cells, wild type and PON2-knockout MEFs 
were exposed to either DMSO or increasing concentrations of C12 for 24 hours 
and cell death was quantified using flow cytometry to detect propidium iodide 
uptake. Data are mean ± standard deviation of three independent experiments. 
n.s. = no significance. Asterisks indicate P values of ˂ 0.05 (*) by student’s 
unpaired t test. 
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Tissues and cells of PON2-knockout mice lack PON2 enzymatic activity  
 To functionally confirm PON2 deficiency in PON2-knockout mice, we 
investigated whether tissues and cells from PON2-knockout mice still possessed 
PON2 enzymatic activity. As a lactonase, the major enzymatic activity of PON2 is 
to hydrolyze lactones[55]. Among the substrates of PON2, C12 is a well-studied 
specific substrate. Via its lactonase activity, PON2 catalyzes the specific hydrolysis 
of the lactone ring of C12 to form a carboxylic acid derivative (C12-COOH; Figure  
5A). The other members of the paraoxonase family, PON1 and PON3, exhibit 
lactonase activity, albeit at orders of magnitude lower than PON2 [1]. Thus, the 
presence of C12-COOH is a reliable indicator of PON2 lactonase activity. 
Therefore, we performed a series of LC-MS experiments in which various lysates 
from wild type and PON2-knockout mice were tested for their activity to hydrolyze 
C12. To detect PON2-mediated hydrolysis of C12, we collaborated with Dr. 
Burlison at the medicinal chemistry facility at the University of Louisville. Whole cell 
lysates from primary MEFs and small intestine tissue isolated from wild type and 
PON2-knockout mice were incubated with either methanol (MeOH) or C12 (in 
MeOH) and analyzed by LC-MS (Figures 5B and 5C). In both small intestine tissue 
and primary MEFs, hydrolysis of C12 (indicated by black arrows) to its carboxylic 
acid derivative C12-COOH (indicated by red arrows) was detected in wild type 
samples. Conversely, the lactonase-opening conversion of C12 to C12-COOH 
was undetectable in both PON2-knockout samples, indicating an absence of 
PON2 enzymatic activity. Because some signals in the chromatograms of the 
PON2-knockout samples may appear to be C12-COOH, the on-board Agilent 
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software analysis suite was used to determine respective measured masses 
(Figures 5D and 5E). In small intestine and primary MEF samples from PON2-
knockout mice, the difference between measured mass of any detected molecule 
and the predicted mass of C12-COOH was orders of magnitude beyond the 
acceptable error value (<5 ppm is acceptable), indicating that C12-COOH was not 
present. The results of these experiments reveal that PON2 enzymatic function is 
absent in tissues and cells collected from mice deficient in PON2 expression. 
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Figure 5. PON2 enzymatic activity is abrogated in tissues and primary cells 
from PON2-knockout mice. To functionally examine the enzymatic activity of 
PON2, lysates of small intestine tissue and primary MEFs were prepared from wild 
type and PON2-knockout mice, treated with either methanol (MeOH) or 50 µM C12 
(in MeOH), and analyzed by liquid chromatography-mass spectrometry (LC-MS). 
(A) PON2 specifically catalyzes the lactone ring-opening hydrolysis of C12 to 
produce a carboxylic acid derivative (C12-COOH). (B) Mass spectra obtained from 
small intestinal tissue lysates exposed to either MeOH or C12. Black arrows 
indicate presence of C12; red arrows indicate presence of C12-COOH. (C) LC-MS 
experiment was repeated under the same conditions with lysates of MEFs from 
wild type and PON2-knockout animals. (D) The masses of identified molecules in 
chromatography spectra of small intestine tissue lysates shown in (B) were 
determined. The molecules whose masses are most similar to predicted C12 mass 
or predicted C12-COOH mass were listed. (E) The mass of identified molecules 
on chromatography spectra shown in (C) was calculated. The molecules with 
masses closest to predicted C12 mass or predicted C12-COOH mass were listed. 
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Systemic PON2 deficiency does not affect mouse growth and development 
Organism-wide changes associated with PON2 deficiency have been 
previously explored, but only in the limited context of serum lipoproteins and 
vascular diseases [2], [29], [30]. To assess whether disruption of the PON2 gene 
expression influences mouse growth and development on a broad scale, we 
monitored mouse body weight biweekly from 4 until 12 weeks of age (Figure 6A), 
at which point organ weight was assessed (Figure 6B). Assessment of body weight 
revealed no significant difference between male wild type and PON2-knockout 
mice, as well as between female wild type and PON2-knockout mice (Figure 6A; 
n=10 per sex per genotype). At the conclusion of the body weight assessment, 
heart, lung, liver, kidney, and spleen organs were removed from a cohort of mice 
(n=5 per sex per genotype) and weighed (Figure 6B). Organ weight was 
normalized to body weight whereupon statistical analysis revealed no significant 
difference between wild type and PON2-knockout mice in respective sex groups. 
Taken together, these observations suggest that PON2 is dispensable for normal 
mouse growth and development. 
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Figure 6. Normal mouse growth and development is unaffected by PON2 
deficiency. (A) Wild type (WT) and homozygous PON2-knockout (PON2-KO) 
C57BL/6J male and female mice (n=10 per group) were weighed biweekly from 4 
weeks until 12 weeks of age. (B) Heart, lung, liver, kidney, and spleen tissues were 
harvested at 12 weeks and weighed from indicated sex and genotype cohorts (n=5 
per group). Data are mean ± standard deviation.  
37 
PON2 plays a vital role in the proliferation of NSCLC cells in vitro 
Since PON2 expression is enhanced in human NSCLC tissues (Figure 1), 
we investigated whether altered PON2 expression would impact proliferation of 
NSCLC cells in vitro. To this purpose, we first generated NSCLC cells with 
decreased PON2 protein levels, accomplished by two approaches: PON2 
knockdown in A549 cells via RNA interference (RNAi) and PON2 knockout in NCI-
H1299 cells via CRISPR/Cas9 (Figure 7). Then we measured cell proliferation by 
monitoring cell number increase in NSCLC cell with different expression levels of 
PON2. A549 cells were infected with lentiviral particles derived from a vector 
expressing either a non-specific scrambled shRNA (control-shRNA) or a PON2-
specific shRNA, and the effects of knockdown were verified by western blot 
analysis (Figure 7A). Equal numbers of both A549 cell types were plated and 
counted daily over 4 days. We observed a significant decrease in total cell number 
in the PON2-shRNA cells compared with the control-shRNA cells (Figure 7B). 
To further address the interplay between PON2 and NSCLC proliferation, 
NCI-H1299 cells were transfected with a vector expressing either a nuclease-
deficient Cas9 with a non-specific scrambled sgRNA, or Cas9 with a PON2-
specific sgRNA. Single clones were established using fluorescence-activated cell 
sorting (FACS), then selected for proliferation experiments based on PON2 
expression; vector clones with unaltered PON2 expression were chosen and 
CRISPR-PON2 clones with undetectable expression were selected (Figure 7C). 
Similar to the observed differences in cell proliferation of A549 cells (Figure 7B), 
NCI-H1299 cells deficient in PON2 expression exhibited a reduced proliferation 
38 
 
over 4 days (Figure 7D). Variations in proliferation of vector cell lines failed to reach 
statistical significance, as did differences in growth of CRISPR-PON2 clones. 
However, both CRISPR-PON2 clones grew at markedly reduced rates compared 
with both vector clones in a statistically significant manner.  The outcomes of these 
experiments indicate that a decrease or elimination of PON2 expression negatively 









Figure 7. PON2 deficiency hinders proliferation of NSCLC cells. (A) PON2 
expression in A549 cells was stably reduced by shRNA. The expression of PON2 
was detected by western blot analysis. The molecular weight markers are labelled 
on the left. (B) Equal numbers of A549 control- and PON2-shRNA cells were plated 
in 12-well plates and cell number was determined using a hemocytometer daily 
over 4 days. Control-shRNA cells proliferated significantly faster than PON2-
shRNA cells by day 4. Data are mean ± standard deviation (n=3); *p<0.05. 
student’s unpaired t test. (C) PON2 expression was determined in parental NCI-
H1299 cells, 2 clonal lines expressing a nuclease-deficient Cas9 and scrambled 
gRNA (vector clones #1 and #2), and 2 clonal lines expressing Cas9 and a gRNA 
specific to human PON2 (CRISPR-PON2 clones #1 and #2). The molecular weight 
markers are labelled on the left. (D) To assess proliferation, an equal number of 
cells from each line were seeded in 12-well plates and counted with a 
hemocytometer daily for 4 days. Data are mean ± standard deviation (n=3); 
*p<0.05 (both vector clones vs. both CRISPR-PON2 clones), **p<0.01 (both vector
clones vs. both CRISPR-PON2 clones). student’s unpaired t test. 
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PON2 expression is not essential for untransformed epithelial cell proliferation 
Next, we sought to determine the effect of reduced PON2 expression on 
proliferation using non-malignant human epithelial cell lines. To accomplish this 
goal, we employed an experimental approach similar to that used in NSCLC 
proliferation experiments (Figure 7). Immortalized human bronchial epithelial 
(HBE) cells [56] or HEK-293Tcells were stably infected with either control shRNA 
lentivirus or PON2-specific shRNA lentivirus. PON2 knockdown was verified via 
western blot analysis (Figure 8A). The proliferation of the cells was evaluated for 
4 days. In contrast to NSCLC cells, the proliferation of both HBE and HEK-293T 
cell lines was unaffected by diminished PON2 expression (Figure 8B). At the end 
of the 4-day experiment, the difference in cell number was not statistically 
significant for both HBE and HEK-293T cells. These data suggest that, unlike 
NSCLC cells, non-malignant human epithelial cells do not require PON2 for their 
proliferation. Furthermore, these results corroborate our in vivo observations that 
mice deficient in PON2 expression develop and grow normally (Figure 6). 
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Figure 8. PON2 knockdown fails to affect untransformed human epithelial 
cell proliferation. Immortalized human bronchial epithelial (HBE) and human 
embryonic kidney-293T (HEK-293T) cells were stably infected with either a non-
specific control shRNA lentivirus or a PON2-specific shRNA lentivirus. The 
molecular weight markers are labelled on the left. (A) PON2 expression was 
evaluated by western blot analysis. (B) Control- and PON2-shRNA expressing 
HBE and HEK-293T cells were plated at a density of 1.5*104 cells in 12-well plates 
and cell number was counted daily for 4 days. Data are mean ± standard deviation 
of 3 independent experiments; n=3.  
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PON2 expression deficiency in NSCLC cells leads to G1 cell cycle arrest. 
To further explore the biological effects of reducing PON2 expression on 
NSCLC cellular proliferation, we carried out cell cycle analysis using flow 
cytometry to evaluate the cell cycle profile of A549 cells expressing either PON2 
shRNA or an empty vector (Figure 9A). We observed an increase in the 
percentage of PON2-deficient cells in the G1 phase of the cell cycle compared 
to the percentage of emtpy vector-expressing cells in the G1 phase. Additionally, 
there was a reduction in the percentage of cells in S phase of the cell cycle in 
PON2-shRNA expressing cells compared to their empty vector-expressing 
counterparts (Figure 9B). Based on these observations, we concluded that 
deficiency in PON2 expression causes cell cycle arrest at G1 phase in A549 
cells. 
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Figure 9. Deficiency in PON2 expression induces G1 cell cycle arrest of 
A549 cells. (A) Cell cycle profiles of A549 cells expressing normal or reduced 
levels of PON2 were evaluated. (B) The data shown in (A) were calculated and 
analyzed. Higher percentage of the cells in G1 phase of cell cycle was found in 
A549 cells with reduced PON2 expression. The data are presented as mean ± 
standard deviation of three independent experiments. Asterisks indicate P 
values of ˂ 0.01 (**) by Student’s unpaired t test.  “ns”, no significance. 
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CHAPTER 4: DISCUSSION 
While previous research efforts have revealed pro-tumorigenic 
contributions of PON2 in a variety of cancer types [33], [38], little attention has been 
given to its role in NSCLC. In the present study, we investigated altered PON2 
expression as it relates to non-malignant and NSCLC cellular growth using various 
experimental paradigms, such as genetically engineered mice, primary cells, as 
well as non-transformed and NSCLC cell lines with altered expression levels of 
PON2. We opted to use biological systems of variable complexity– cell-free 
systems, well-established cell lines, primary cells, mouse and human tissues, and 
whole-organism experiments– to thoroughly investigate PON2’s potential utility as 
a selective target to impede NSCLC proliferation. 
Previous studies have largely concluded that PON2 plays a pro-tumorigenic 
role through numerous proposed mechanisms. A recent large-scale study was 
performed by analyzing RNA- and DNA-sequencing data collected from over 
10,000 patients with more than 30 types of cancer to interrogate whether PON2 
mutations and expression impact patient outcomes [42]. Indeed, the researchers 
established a negative correlation between PON2 expression and patient 
prognosis across numerous types of neoplastic disease. Similarly, Witte et al. 
surveyed hundreds of patient samples from dozens of cancer types to discover 
upregulation of PON2 in numerous solid tumors, leukemias, and lymphomas [38].
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Subsequent PON2 knockdown or overexpression experiments indicate that PON2 
mitigates ER stress and prevents the activation of the intrinsic apoptotic pathway 
[54], [57] . 
Despite the implication of PON2 in a multitude of cancers, research into 
specific tumor types has been limited. In the context of oral squamous cell 
carcinoma (OSCC), Kruger et al. described PON2 overexpression in tumors 
isolated from patients with OSCC and proposed that PON2’s anti-apoptotic effects 
are regulated through the Wnt/β-catenin network [39], [40]. Interestingly, one 
published report examined the role of PON2 in pancreatic ductal adenocarcinoma 
and expanded its functions to preventing the cellular starvation response to 
promote tumor growth, anchorage-independence, and metastasis to distant sites 
[41]. Similarly, Bacchetti et al. characterized differences in PON2 expression using 
human bladder cancer tumors of various stages [58]. In addition to solid tumor 
studies, PON2 has also been identified in gene expression profiles of imatinib-
resistant chronic myelogenous leukemia [34] and subsets of pediatric acute 
lymphoblastic leukemia [37]. In stark opposition to these reports, Devarajan et al. 
suggested a tumor suppressor function for PON2 using a xenograft model of 
ovarian cancer in mice [59]. While this is the only such finding of an anti-tumor 
effect of PON2 upregulation, it warrants further investigation. 
 PON2-knockout mice were previously generated by Ng and colleagues  to 
study the protective role of PON2 during the development of atherosclerotic 
plaques [30]. These researchers used a gene-trapping method, which has been 
characterized as having the potential pitfall of allowing leaky expression of the 
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trapped gene [51]–[53]. Other groups have also utilized this particular mouse strain 
to investigate the influence of PON2 on vascular disease[28]–[30], [60]. To prevent 
confounding results due to aberrant PON2 expression in vivo, we employed a 
CRISPR/Cas9 approach to systemically disrupt the PON2 locus in mice. In major 
organs known to harbor high levels of PON2 protein (heart, lung, small intestine, 
and large intestine), PON2 was undetectable by western blot in homozygous 
mutant mice, indicating a complete and robust knockout (Figure 3). Additionally, 
we assessed PON2 enzymatic activity in small intestine tissue and primary MEFs 
using LC-MS to detect the hydrolysis of C12 to its carboxylic acid derivative (Figure 
5). The presence of C12-COOH was detected in lysates prepared from WT, but 
not PON2-knockout mice, which confirms that PON2 activity is lost in animals with 
homozygous PON2 mutations. To further determine PON2 biological function, we 
treated primary MEFs from wild type or PON2-knockout mice with increasing 
concentrations of C12, whose cytotoxicity depends on PON2 lactonase activity [1]. 
We observed a dose-dependent decrease in cell viability following treatment with 
C12 in wild type, but not PON2-knockout MEFs (Figure 4), correlating PON2 status 
with C12-mediated cell death. 
In contrast to other reports which analyzed the physiological consequences 
of PON2 depletion in the presence of an atherogenic diet or other genetic 
manipulations [29], [30], the present study is the first to monitor mouse growth in 
the context of PON2 knockout per se. To this purpose, we found that mice lacking 
PON2 exhibit normal body and organ weight compared with wild type mice (Figure 
3). While more extensive anatomical and physiological examinations may uncover 
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evidence to the contrary, these observations suggest that PON2 is not required for 
normal mouse growth and development. 
The disposable nature of PON2 expression for non-malignant cell 
proliferation is further corroborated by RNAi experiments in which PON2 
expression was decreased in non-transformed HBE and HEK-293T cells (Figure 
8). In both cell lines, PON2 knockdown failed to affect cell proliferation in vitro. 
These observations, coupled with the knockout animal experiments (Figure 6), 
strengthen the notion that PON2 expression may be depleted with no disruption to 
normal tissue homeostasis.  
 In contrast with the aforementioned observations, PON2 depletion in 
NSCLC markedly reduced cellular proliferation (Figure 7). Using two separate 
approaches to disrupt PON2 expression– RNAi in A549 cells and CRISPR/Cas9-
mediated knockout in NCI-H1299 cells– we observed significant reductions in cell 
number using both heterogeneous bulk populations (A549) and clonal cell lines 
(NCI-H1299). These observations indicate that PON2, while dispensable in non-
transformed cells, is required for NSCLC cell proliferation. 
In this study, using PON2-deficient mice, primary mouse cells, and NSCLC 
cell lines with altered PON2 expression, we have demonstrated that PON2 exhibits 
characteristics favorable for a potential therapeutic target against NSCLC: Its 
expression is not required for non-malignant cell proliferation, mouse growth and 
development is unaffected by PON2 deletion, and NSCLC cells require PON2 for 
their proliferation. Taken together, these properties highlight PON2 as a potentially 
important target in halting the proliferation of established NSCLC tumors
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CHAPTER 5: CONCLUSION 
 
 In the present study, we highlighted PON2 as a unique vulnerability in 
NSCLC proliferation. This concept was demonstrated using PON2-knockout mice, 
tissue samples from patients with NSCLC, as well as normal and malignant cell 
lines with altered PON2 expression. The results of this study indicate that 
disruption of PON2, while inconsequential for non-transformed tissue, 
detrimentally alters NSCLC physiology in a manner that may be exploited for 
therapeutic benefit. Taken in conjunction with previous reports, PON2 represents 
an intriguing aspect of tumor biology that merits further investigation.  
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